• Pharming secured European Commission marketing authorization for Joenja (leniolisib) to treat activated PI3K delta syndrome in patients aged 12 and older, marking the first approved therapy for the condition in the EU.
• First European launch is expected in Germany in Q3 2026, with broader rollout tied to national reimbursement talks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605221530PRIMZONEFULLFEED1001183635) on May 22, 2026, and is solely responsible for the information contained therein.